Advancing Novel Therapeutics for Rare Hemoglobinopathies
Our pipeline is built on the differentiated therapeutic potential of IMR-687, which is
an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia.
IMR-687: A Multimodal Mechanism of Action
IMR-687 is a highly selective, potent small molecule inhibitor of PDE9 that has a multimodal MOA that acts primarily on red blood cells and has the potential to act on white blood cells, adhesion mediators and other cell types that are implicated in sickle cell disease.
Motivated by Patients
Imara is dedicated to making a difference in the lives of patients, their families, and the broader communities affected by sickle cell disease and beta-thalassemia.
